GIPR and obesity due to melanocortin 4 receptor deficiency: Although our results together with several studies of anti-GIPR antibodies (Gault et al., 2005; Killion et al., 2018; Min et al., 2020; Svendsen et al., 2020; Chen et al., 2021) could indicate that GIPR antagonists could protect from diet-induced obesity and improve glycemic and insulinotropic effects, other studies have shown the same for GIPR agonists (Nørregaard et al., 2018; Mroz et al., 2019; Samms et al., 2021).